afamelanotide - HEALTHIES
MELBOURNE, Australia, (GLOBE NEWSWIRE) -- CLINUVEL today announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease (PD or Parkinson’s) ... Pharmabiz: Clinuvel Pharma’s second afamelanotide formulation drug, Prénumbra to be evaluated in patients with acute and systemic diseases Clinuvel Pharmaceuticals revealed Prénumbra the company’s second afamelanotide product in development. Prénumbra is a liquid (non-solid) formulation of afamelanotide to be evaluated by Clinuvel in ...
Understanding the Context
Clinuvel Pharma’s second afamelanotide formulation drug, Prénumbra to be evaluated in patients with acute and systemic diseases MELBOURNE, Australia and SINGAPORE, (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS today revealed PRÉNUMBRA ®, the Company’s second afamelanotide product in development. PRÉNUMBRA ® is a ... Scenesse (Clinuvel Pharmaceuticals) is a bimonthly, subcutaneous dose of afamelanotide 16mg. A New Drug Application (NDA) for the treatment of erythropoietic protoporphyria (EPP) – a rare blood ...
Image Gallery
Key Insights
The US Food and Drug Administration (FDA) has approved afamelanotide (Scenesse, Clinuvel), the first treatment to ease phototoxic reactions in patients with erythropoietic protoporphyria, according to ... Please provide your email address to receive an email when new articles are posted on . Researchers discovered that a combination of afamelanotide and NB-UV-B phototherapy resulted in statistically ... National Institute for Health and Care Excellence: Afamelanotide for treating erythropoietic protoporphyria The Department of Health has asked the National Institute for Health and Care Excellence (NICE) to produce guidance on using afamelanotide in the context of national commissioning by NHS England. The ...